Antifungal Agents
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
Effect of Calcium Silicate-Based Root Canal Medicament After Retreatment
Amphotericin B for Non-HIV Cryptococcal Meningitis Patients
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients
Screening Anti-Fungal Exposure in Intensive Care Units